 | • レポートコード：QAF27588 • 出版社/出版日：QYResearch / 2021年4月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、147ページ • 納品方法：Eメール（即日納品） • 産業分類：医薬品 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査資料では、世界の生物製剤＆バイオシミラー市場について種類別（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他）、用途別（腫瘍、糖尿病、心血管、血友病、その他）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・生物製剤＆バイオシミラー市場の概要 ・世界の主要地域別生物製剤＆バイオシミラー市場規模2016-2027 ・主要プレイヤーの競争状況・市場シェア ・世界の生物製剤＆バイオシミラー市場規模2016-2021：種類別（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他） ・世界の生物製剤＆バイオシミラー市場予測2012-2027：種類別（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他） ・世界の生物製剤＆バイオシミラー市場規模2016-2021：用途別（腫瘍、糖尿病、心血管、血友病、その他） ・世界の生物製剤＆バイオシミラー市場予測2012-2027：用途別（腫瘍、糖尿病、心血管、血友病、その他） ・生物製剤＆バイオシミラーのアメリカ市場規模と予測2016-2021 ・生物製剤＆バイオシミラーのヨーロッパ市場規模と予測2016-2021 ・生物製剤＆バイオシミラーの中国市場規模と予測2016-2021 ・生物製剤＆バイオシミラーの日本市場規模と予測2016-2021 ・生物製剤＆バイオシミラーの東南アジア市場規模と予測2016-2021 ・生物製剤＆バイオシミラーのインド市場規模と予測2016-2021 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Roche、Amgen、AbbVie、Sanofi-Aventis、Johnson & Johnson、Pfizer、Novo Nordisk、Eli Lilly、Novartis、Merck、3sbio、Changchun High Tech、CP Guojian、Biotech、Gelgen、Innovent、Dong Bao、Ganlee） ・生物製剤＆バイオシミラーの製造コスト分析 ・販売チャネル、流通業者、顧客 ・生物製剤＆バイオシミラーの市場動向・機会・課題 ・調査の結論 |
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.
The research shows that the growth of biologics industry may be slow but high profits during the period of patent may be attractive to newcomers.
Market Analysis and Insights: Global Biologics and Biosimilars Market
The global Biologics and Biosimilars market was valued at US$ 322440 in 2020 and will reach US$ 508830 million by the end of 2027, growing at a CAGR of 7.9% during 2022-2027.
Global Biologics and Biosimilars Scope and Market Size
The global Biologics and Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologics and Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
The Biologics and Biosimilars market is analysed and market size information is provided by regions (countries). Segment by Application, the Biologics and Biosimilars market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
1 Biologics and Biosimilars Market Overview
1.1 Biologics and Biosimilars Product Scope
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales by Type (2016 & 2021 & 2027)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Global Biologics and Biosimilars Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Biologics and Biosimilars Market Estimates and Forecasts (2016-2027)
1.4.1 Global Biologics and Biosimilars Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Biologics and Biosimilars Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Biologics and Biosimilars Price Trends (2016-2027)
2 Biologics and Biosimilars Estimates and Forecasts by Region
2.1 Global Biologics and Biosimilars Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Biologics and Biosimilars Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
2.2.2 Global Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
2.3 Global Biologics and Biosimilars Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Biologics and Biosimilars Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Biologics and Biosimilars Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Biologics and Biosimilars Estimates and Projections (2016-2027)
2.4.2 Europe Biologics and Biosimilars Estimates and Projections (2016-2027)
2.4.3 China Biologics and Biosimilars Estimates and Projections (2016-2027)
2.4.4 Japan Biologics and Biosimilars Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Biologics and Biosimilars Estimates and Projections (2016-2027)
2.4.6 India Biologics and Biosimilars Estimates and Projections (2016-2027)
3 Global Biologics and Biosimilars Competition Landscape by Players
3.1 Global Top Biologics and Biosimilars Players by Sales (2016-2021)
3.2 Global Top Biologics and Biosimilars Players by Revenue (2016-2021)
3.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biologics and Biosimilars as of 2020)
3.4 Global Biologics and Biosimilars Average Price by Company (2016-2021)
3.5 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Biologics and Biosimilars Market Size by Type
4.1 Global Biologics and Biosimilars Historic Market Review by Type (2016-2021)
4.1.1 Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
4.1.2 Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
4.1.3 Global Biologics and Biosimilars Price by Type (2016-2021)
4.2 Global Biologics and Biosimilars Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Biologics and Biosimilars Sales Forecast by Type (2022-2027)
4.2.2 Global Biologics and Biosimilars Revenue Forecast by Type (2022-2027)
4.2.3 Global Biologics and Biosimilars Price Forecast by Type (2022-2027)
5 Global Biologics and Biosimilars Market Size by Application
5.1 Global Biologics and Biosimilars Historic Market Review by Application (2016-2021)
5.1.1 Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
5.1.2 Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
5.1.3 Global Biologics and Biosimilars Price by Application (2016-2021)
5.2 Global Biologics and Biosimilars Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Biologics and Biosimilars Sales Forecast by Application (2022-2027)
5.2.2 Global Biologics and Biosimilars Revenue Forecast by Application (2022-2027)
5.2.3 Global Biologics and Biosimilars Price Forecast by Application (2022-2027)
6 North America Biologics and Biosimilars Market Facts & Figures
6.1 North America Biologics and Biosimilars Sales by Company
6.1.1 North America Biologics and Biosimilars Sales by Company (2016-2021)
6.1.2 North America Biologics and Biosimilars Revenue by Company (2016-2021)
6.2 North America Biologics and Biosimilars Sales Breakdown by Type
6.2.1 North America Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
6.2.2 North America Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
6.3 North America Biologics and Biosimilars Sales Breakdown by Application
6.3.1 North America Biologics and Biosimilars Sales Breakdown by Application (2016-2021)
6.3.2 North America Biologics and Biosimilars Sales Breakdown by Application (2022-2027)
7 Europe Biologics and Biosimilars Market Facts & Figures
7.1 Europe Biologics and Biosimilars Sales by Company
7.1.1 Europe Biologics and Biosimilars Sales by Company (2016-2021)
7.1.2 Europe Biologics and Biosimilars Revenue by Company (2016-2021)
7.2 Europe Biologics and Biosimilars Sales Breakdown by Type
7.2.1 Europe Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
7.2.2 Europe Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
7.3 Europe Biologics and Biosimilars Sales Breakdown by Application
7.3.1 Europe 147 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 147 Sales Breakdown by Application (2022-2027)
8 China Biologics and Biosimilars Market Facts & Figures
8.1 China Biologics and Biosimilars Sales by Company
8.1.1 China Biologics and Biosimilars Sales by Company (2016-2021)
8.1.2 China Biologics and Biosimilars Revenue by Company (2016-2021)
8.2 China Biologics and Biosimilars Sales Breakdown by Type
8.2.1 China Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
8.2.2 China Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
8.3 China Biologics and Biosimilars Sales Breakdown by Application
8.3.1 China 315 Sales Breakdown by Application (2016-2021)
8.3.2 China 315 Sales Breakdown by Application (2022-2027)
9 Japan Biologics and Biosimilars Market Facts & Figures
9.1 Japan Biologics and Biosimilars Sales by Company
9.1.1 Japan Biologics and Biosimilars Sales by Company (2016-2021)
9.1.2 Japan Biologics and Biosimilars Revenue by Company (2016-2021)
9.2 Japan Biologics and Biosimilars Sales Breakdown by Type
9.2.1 Japan Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
9.2.2 Japan Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
9.3 Japan Biologics and Biosimilars Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Biologics and Biosimilars Market Facts & Figures
10.1 Southeast Asia Biologics and Biosimilars Sales by Company
10.1.1 Southeast Asia Biologics and Biosimilars Sales by Company (2016-2021)
10.1.2 Southeast Asia Biologics and Biosimilars Revenue by Company (2016-2021)
10.2 Southeast Asia Biologics and Biosimilars Sales Breakdown by Type
10.2.1 Southeast Asia Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Biologics and Biosimilars Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India Biologics and Biosimilars Market Facts & Figures
11.1 India Biologics and Biosimilars Sales by Company
11.1.1 India Biologics and Biosimilars Sales by Company (2016-2021)
11.1.2 India Biologics and Biosimilars Revenue by Company (2016-2021)
11.2 India Biologics and Biosimilars Sales Breakdown by Type
11.2.1 India Biologics and Biosimilars Sales Breakdown by Type (2016-2021)
11.2.2 India Biologics and Biosimilars Sales Breakdown by Type (2022-2027)
11.3 India Biologics and Biosimilars Sales Breakdown by Application
11.3.1 India Biologics and Biosimilars Sales Breakdown by Application (2016-2021)
11.3.2 India Biologics and Biosimilars Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Biologics and Biosimilars Business
12.1 Roche
12.1.1 Roche Corporation Information
12.1.2 Roche Business Overview
12.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Roche Biologics and Biosimilars Products Offered
12.1.5 Roche Recent Development
12.2 Amgen
12.2.1 Amgen Corporation Information
12.2.2 Amgen Business Overview
12.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Amgen Biologics and Biosimilars Products Offered
12.2.5 Amgen Recent Development
12.3 AbbVie
12.3.1 AbbVie Corporation Information
12.3.2 AbbVie Business Overview
12.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.3.4 AbbVie Biologics and Biosimilars Products Offered
12.3.5 AbbVie Recent Development
12.4 Sanofi-Aventis
12.4.1 Sanofi-Aventis Corporation Information
12.4.2 Sanofi-Aventis Business Overview
12.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sanofi-Aventis Biologics and Biosimilars Products Offered
12.4.5 Sanofi-Aventis Recent Development
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Corporation Information
12.5.2 Johnson & Johnson Business Overview
12.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Johnson & Johnson Biologics and Biosimilars Products Offered
12.5.5 Johnson & Johnson Recent Development
12.6 Pfizer
12.6.1 Pfizer Corporation Information
12.6.2 Pfizer Business Overview
12.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Pfizer Biologics and Biosimilars Products Offered
12.6.5 Pfizer Recent Development
12.7 Novo Nordisk
12.7.1 Novo Nordisk Corporation Information
12.7.2 Novo Nordisk Business Overview
12.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Novo Nordisk Biologics and Biosimilars Products Offered
12.7.5 Novo Nordisk Recent Development
12.8 Eli Lilly
12.8.1 Eli Lilly Corporation Information
12.8.2 Eli Lilly Business Overview
12.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Eli Lilly Biologics and Biosimilars Products Offered
12.8.5 Eli Lilly Recent Development
12.9 Novartis
12.9.1 Novartis Corporation Information
12.9.2 Novartis Business Overview
12.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Novartis Biologics and Biosimilars Products Offered
12.9.5 Novartis Recent Development
12.10 Merck
12.10.1 Merck Corporation Information
12.10.2 Merck Business Overview
12.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Merck Biologics and Biosimilars Products Offered
12.10.5 Merck Recent Development
12.11 3sbio
12.11.1 3sbio Corporation Information
12.11.2 3sbio Business Overview
12.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.11.4 3sbio Biologics and Biosimilars Products Offered
12.11.5 3sbio Recent Development
12.12 Changchun High Tech
12.12.1 Changchun High Tech Corporation Information
12.12.2 Changchun High Tech Business Overview
12.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Changchun High Tech Biologics and Biosimilars Products Offered
12.12.5 Changchun High Tech Recent Development
12.13 CP Guojian
12.13.1 CP Guojian Corporation Information
12.13.2 CP Guojian Business Overview
12.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.13.4 CP Guojian Biologics and Biosimilars Products Offered
12.13.5 CP Guojian Recent Development
12.14 Biotech
12.14.1 Biotech Corporation Information
12.14.2 Biotech Business Overview
12.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Biotech Biologics and Biosimilars Products Offered
12.14.5 Biotech Recent Development
12.15 Gelgen
12.15.1 Gelgen Corporation Information
12.15.2 Gelgen Business Overview
12.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Gelgen Biologics and Biosimilars Products Offered
12.15.5 Gelgen Recent Development
12.16 Innovent
12.16.1 Innovent Corporation Information
12.16.2 Innovent Business Overview
12.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Innovent Biologics and Biosimilars Products Offered
12.16.5 Innovent Recent Development
12.17 Dong Bao
12.17.1 Dong Bao Corporation Information
12.17.2 Dong Bao Business Overview
12.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Dong Bao Biologics and Biosimilars Products Offered
12.17.5 Dong Bao Recent Development
12.18 Ganlee
12.18.1 Ganlee Corporation Information
12.18.2 Ganlee Business Overview
12.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Ganlee Biologics and Biosimilars Products Offered
12.18.5 Ganlee Recent Development
13 Biologics and Biosimilars Manufacturing Cost Analysis
13.1 Biologics and Biosimilars Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Biologics and Biosimilars
13.4 Biologics and Biosimilars Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Biologics and Biosimilars Distributors List
14.3 Biologics and Biosimilars Customers
15 Market Dynamics
15.1 Biologics and Biosimilars Market Trends
15.2 Biologics and Biosimilars Drivers
15.3 Biologics and Biosimilars Market Challenges
15.4 Biologics and Biosimilars Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Biologics and Biosimilars Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Biologics and Biosimilars Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Biologics and Biosimilars Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Biologics and Biosimilars Sales (K Units) by Region (2016-2021)
Table 5. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 6. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Biologics and Biosimilars Revenue Share by Region (2016-2021)
Table 8. Global Biologics and Biosimilars Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global Biologics and Biosimilars Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Biologics and Biosimilars Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Biologics and Biosimilars Revenue Share Forecast by Region (2022-2027)
Table 12. Global Biologics and Biosimilars Sales (K Units) of Key Companies (2016-2021)
Table 13. Global Biologics and Biosimilars Sales Share by Company (2016-2021)
Table 14. Global Biologics and Biosimilars Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Biologics and Biosimilars Revenue Share by Company (2016-2021)
Table 16. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2020)
Table 17. Global Biologics and Biosimilars Average Price (USD/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Biologics and Biosimilars Manufacturing Sites and Area Served
Table 19. Manufacturers Biologics and Biosimilars Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Biologics and Biosimilars Sales (K Units) by Type (2016-2021)
Table 22. Global Biologics and Biosimilars Sales Share by Type (2016-2021)
Table 23. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Biologics and Biosimilars Price (USD/Unit) by Type (2016-2021)
Table 25. Global Biologics and Biosimilars Sales Share by Type (2022-2027)
Table 26. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Biologics and Biosimilars Revenue Share by Type (2022-2027)
Table 28. Global Biologics and Biosimilars Price (USD/Unit) by Type (2022-2027)
Table 29. Global Biologics and Biosimilars Sales (K Units) by Application (2016-2021)
Table 30. Global Biologics and Biosimilars Sales Share by Application (2016-2021)
Table 31. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Biologics and Biosimilars Price (USD/Unit) by Application (2016-2021)
Table 33. Global Biologics and Biosimilars Sales (K Units) by Application (2022-2027)
Table 34. Global Biologics and Biosimilars Sales Share by Application (2022-2027)
Table 35. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Biologics and Biosimilars Revenue Share by Application (2022-2027)
Table 37. Global Biologics and Biosimilars Price (USD/Unit) by Application (2022-2027)
Table 38. North America Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 39. North America Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 40. North America Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 42. North America Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 43. North America Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 44. North America Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 45. North America Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 46. North America Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 47. North America Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 48. North America Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 49. North America Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 50. Europe Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 51. Europe Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 52. Europe Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 54. Europe Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 55. Europe Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 56. Europe Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 57. Europe Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 58. Europe Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 59. Europe Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 60. Europe Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 61. Europe Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 62. China Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 63. China Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 64. China Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 66. China Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 67. China Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 68. China Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 69. China Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 70. China Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 71. China Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 72. China Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 73. China Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 74. Japan Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 75. Japan Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 76. Japan Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 78. Japan Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 79. Japan Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 80. Japan Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 81. Japan Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 82. Japan Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 83. Japan Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 84. Japan Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 85. Japan Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 98. India Biologics and Biosimilars Sales (K Units) by Company (2016-2021)
Table 99. India Biologics and Biosimilars Sales Market Share by Company (2016-2021)
Table 100. India Biologics and Biosimilars Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Biologics and Biosimilars Revenue Market Share by Company (2016-2021)
Table 102. India Biologics and Biosimilars Sales by Type (2016-2021) & (K Units)
Table 103. India Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 104. India Biologics and Biosimilars Sales by Type (2022-2027) & (K Units)
Table 105. India Biologics and Biosimilars Sales Market Share by Type (2022-2027)
Table 106. India Biologics and Biosimilars Sales by Application (2016-2021) & (K Units)
Table 107. India Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 108. India Biologics and Biosimilars Sales by Application (2022-2027) & (K Units)
Table 109. India Biologics and Biosimilars Sales Market Share by Application (2022-2027)
Table 110. Roche Corporation Information
Table 111. Roche Description and Business Overview
Table 112. Roche Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Roche Biologics and Biosimilars Product
Table 114. Roche Recent Development
Table 115. Amgen Corporation Information
Table 116. Amgen Description and Business Overview
Table 117. Amgen Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Amgen Biologics and Biosimilars Product
Table 119. Amgen Recent Development
Table 120. AbbVie Corporation Information
Table 121. AbbVie Description and Business Overview
Table 122. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. AbbVie Biologics and Biosimilars Product
Table 124. AbbVie Recent Development
Table 125. Sanofi-Aventis Corporation Information
Table 126. Sanofi-Aventis Description and Business Overview
Table 127. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Sanofi-Aventis Biologics and Biosimilars Product
Table 129. Sanofi-Aventis Recent Development
Table 130. Johnson & Johnson Corporation Information
Table 131. Johnson & Johnson Description and Business Overview
Table 132. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Johnson & Johnson Biologics and Biosimilars Product
Table 134. Johnson & Johnson Recent Development
Table 135. Pfizer Corporation Information
Table 136. Pfizer Description and Business Overview
Table 137. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. Pfizer Biologics and Biosimilars Product
Table 139. Pfizer Recent Development
Table 140. Novo Nordisk Corporation Information
Table 141. Novo Nordisk Description and Business Overview
Table 142. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 143. Novo Nordisk Biologics and Biosimilars Product
Table 144. Novo Nordisk Recent Development
Table 145. Eli Lilly Corporation Information
Table 146. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 147. Eli Lilly Description and Business Overview
Table 148. Eli Lilly Biologics and Biosimilars Product
Table 149. Eli Lilly Recent Development
Table 150. Novartis Corporation Information
Table 151. Novartis Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 152. Novartis Description and Business Overview
Table 153. Novartis Biologics and Biosimilars Product
Table 154. Novartis Recent Development
Table 155. Merck Corporation Information
Table 156. Merck Description and Business Overview
Table 157. Merck Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 158. Merck Biologics and Biosimilars Product
Table 159. Merck Recent Development
Table 160. 3sbio Corporation Information
Table 161. 3sbio Description and Business Overview
Table 162. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 163. 3sbio Biologics and Biosimilars Product
Table 164. 3sbio Recent Development
Table 165. Changchun High Tech Corporation Information
Table 166. Changchun High Tech Description and Business Overview
Table 167. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 168. Changchun High Tech Biologics and Biosimilars Product
Table 169. Changchun High Tech Recent Development
Table 170. CP Guojian Corporation Information
Table 171. CP Guojian Description and Business Overview
Table 172. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 173. CP Guojian Biologics and Biosimilars Product
Table 174. CP Guojian Recent Development
Table 175. Biotech Corporation Information
Table 176. Biotech Description and Business Overview
Table 177. Biotech Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 178. Biotech Biologics and Biosimilars Product
Table 179. Biotech Recent Development
Table 180. Gelgen Corporation Information
Table 181. Gelgen Description and Business Overview
Table 182. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 183. Gelgen Biologics and Biosimilars Product
Table 184. Gelgen Recent Development
Table 185. Innovent Corporation Information
Table 186. Innovent Description and Business Overview
Table 187. Innovent Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 188. Innovent Biologics and Biosimilars Product
Table 189. Innovent Recent Development
Table 190. Dong Bao Corporation Information
Table 191. Dong Bao Description and Business Overview
Table 192. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 193. Dong Bao Biologics and Biosimilars Product
Table 194. Dong Bao Recent Development
Table 195. Ganlee Corporation Information
Table 196. Ganlee Description and Business Overview
Table 197. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 198. Ganlee Biologics and Biosimilars Product
Table 199. Ganlee Recent Development
Table 200. Production Base and Market Concentration Rate of Raw Material
Table 201. Key Suppliers of Raw Materials
Table 202. Biologics and Biosimilars Distributors List
Table 203. Biologics and Biosimilars Customers List
Table 204. Biologics and Biosimilars Market Trends
Table 205. Biologics and Biosimilars Market Drivers
Table 206. Biologics and Biosimilars Market Challenges
Table 207. Biologics and Biosimilars Market Restraints
Table 208. Research Programs/Design for This Report
Table 209. Key Data Information from Secondary Sources
Table 210. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Biologics and Biosimilars Sales Market Share by Application in 2021 & 2027
Figure 6. Tumor Examples
Figure 7. Diabetes Examples
Figure 8. Cardiovascular Examples
Figure 9. Hemophilia Examples
Figure 10. Others Examples
Figure 11. Global Biologics and Biosimilars Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Biologics and Biosimilars Sales Growth Rate (2016-2027) & (US$ Million)
Figure 13. Global Biologics and Biosimilars Sales (K Units) Growth Rate (2016-2027)
Figure 14. Global Biologics and Biosimilars Price Trends Growth Rate (2016-2027) (USD/Unit)
Figure 15. Global Biologics and Biosimilars Revenue Market Share by Region: 2016 VS 2021
Figure 16. Global Biologics and Biosimilars Revenue Market Share by Region: 2021 VS 2027
Figure 17. North America Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. North America Biologics and Biosimilars Sales (K Units) Growth Rate (2016-2027)
Figure 19. Europe Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. Europe Biologics and Biosimilars Sales (Million USD) Growth Rate (2016-2027)
Figure 21. China Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. China Biologics and Biosimilars Sales (Million USD) and Growth Rate (2016-2027)
Figure 23. Japan Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Japan Biologics and Biosimilars Sales (Million USD) Growth Rate (2016-2027)
Figure 25. Southeast Asia Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. Southeast Asia Biologics and Biosimilars Sales (Million USD) Growth Rate (2016-2027)
Figure 27. India Biologics and Biosimilars Revenue (Million USD) Growth Rate (2016-2027)
Figure 28. India Biologics and Biosimilars Sales (Million USD) Growth Rate (2016-2027)
Figure 29. Global 5 Largest Biologics and Biosimilars Players Market Share by Revenue in Biologics and Biosimilars: 2016 & 2020
Figure 30. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 31. Global Biologics and Biosimilars Revenue Share by Type (2016-2021)
Figure 32. Global Biologics and Biosimilars Revenue Growth Rate by Type in 2016 & 2020
Figure 33. Global Biologics and Biosimilars Revenue Share by Application (2016-2021)
Figure 34. Global Biologics and Biosimilars Revenue Growth Rate by Application in 2016 & 2020
Figure 35. North America Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 36. North America Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 37. Europe Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 38. Europe Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 39. China Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 40. China Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 41. Japan Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 42. Japan Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 43. Southeast Asia Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 44. Southeast Asia Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 45. India Biologics and Biosimilars Sales Market Share by Type in 2020
Figure 46. India Biologics and Biosimilars Sales Market Share by Application in 2020
Figure 47. Key Raw Materials Price Trend
Figure 48. Manufacturing Cost Structure of Biologics and Biosimilars
Figure 49. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 50. Biologics and Biosimilars Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
世界の網膜用バイオシミラー市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Retinal Biosimilars Market The global Retinal Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report mak…- バイオシミラーのグローバル市場調査 2019年 The global Biosimilars market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Biosimilars volume and value at global level, regional level and company level. From a global perspective, this report represen…
- 世界のGMP生物製剤市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global GMP Biologics Market The global GMP Biologics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brillia…
- 世界の網膜用生物製剤市場規模・現状・予測（2021年-2027年） Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat r…
- 世界の生物製剤受託機関（CDMO）市場規模・現状・予測（2021年-2027年） In this emerging in the form of cooperation, biological medicine industry further extended to the biological agents in the form of outsourcing cooperation contract development and manufacturing organization (CDMO) mode, the CDMO from preclinical studies and clinical trials to commercial production s…